In conclusion, our study was able to show that the combination of disease‐specific tau‐PET binding pattern and CSF p‐tau181 status can be used as a reliable diagnostic biomarker‐based algorithm to differentiate between AD and 4RTs. This evidence concerns the gene MAPT and Alzheimer disease.